Biomotion Sciences Ordinary Shares - Asset Resilience Ratio
Biomotion Sciences Ordinary Shares (SLXN) has an Asset Resilience Ratio of 1.22% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Biomotion Sciences Ordinary Shares to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2024)
This chart shows how Biomotion Sciences Ordinary Shares's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SLXN total asset value.
Liquid Assets Composition Over Time
This chart breaks down Biomotion Sciences Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SLXN total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $35.00K | 1.22% |
| Total Liquid Assets | $35.00K | 1.22% |
Asset Resilience Insights
- Limited Liquidity: Biomotion Sciences Ordinary Shares maintains only 1.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biomotion Sciences Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Biomotion Sciences Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Biomotion Sciences Ordinary Shares (2024–2024)
The table below shows the annual Asset Resilience Ratio data for Biomotion Sciences Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.22% | $35.00K | $2.86 Million | -- |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more